Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Revolution Medicines $300 million follow-on offering
We advised the underwriters in connection with the equity offering
Ocumension Therapeutics HK$793.8 million top-up placement of shares
We advised the placing agent in connection with the equity offering
Venus Medtech HK$1.4 billion placing of new H shares
We advised Venus Medtech (Hangzhou) on its placement of new shares
CureVac $450 million public offering
We advised CureVac on the equity offering
Seer $251.3 million stock offering
We advised the underwriters on the SEC-registered equity offering
Surgalign Holdings $37.5 million follow-on offering
We advised the underwriters on the equity offering
Personalis, Inc. $150 million stock offering
We advised the underwriters on the equity offering
Precigen $129 million common stock offering
We advised the underwriters in connection with the SEC-registered equity offering
Cryoport $287.5 million follow-on offering
We advised the underwriters on the SEC-registered offering
CytomX Therapeutics $100 million follow-on offering
We advised the joint book-running managers in connection with the equity offering